🔥 Eli Lilly Just Put Its $299 Weight-Loss Shot Straight on Hims & Hers — and the Stock Popped 7%

You can now buy Eli Lilly’s blockbuster weight-loss shot Zepbound for $299 a month without ever leaving the Hims & Hers website. That one sentence moved a $6 billion company.

On Friday, November 6, Lilly said Hims & Hers can sell its obesity drugs — the Zepbound injection and the newer Foundayo pill — directly on its platform (Reuters via Investing.com). Until now, a Hims customer who wanted Lilly’s medicine got bounced off the site to LillyDirect, Lilly’s own cash-pay pharmacy, to finish the order. Every extra click is a chance to give up.

Investors liked the friction disappearing. HIMS jumped about 7% in premarket trading, touching $25.70, while Lilly slipped roughly 1% to $1,352.40 (MoneyCheck).

The thesis: the GLP-1 gold rush has moved from “can you get the drug” to “how cheaply can you get it to someone’s door,” and the telehealth checkout page is now the battleground.

🧠 Why This Matters

Weight-loss drugs are increasingly bought with cash, not insurance. Lilly says 40% to 45% of Zepbound sales already go through self-pay channels (Reuters via Investing.com). When nearly half your sales bypass pharmacy benefit managers, the company that owns the easiest checkout owns the customer.

Hims & Hers has spent 2026 turning itself into that checkout. It added Novo Nordisk’s Wegovy and Ozempic back in March. With Lilly now on board directly, Hims carries both of the two companies that matter in this market on the same digital shelf.

Leerink Partners analyst Michael Cherny called the partnership “a clear positive,” saying it completes Hims & Hers’ access to the two leading GLP-1 drugmakers.

For Lilly, the logic is just as plain. “The ease and ability for someone on the Hims & Hers platform today to get Lilly medicine is not fully straightforward,” said Ilya Yuffa, president of Lilly USA (Reuters via Investing.com). Translation: friction was costing sales, and Lilly just removed it.

📊 Deep Dive

The prices are the whole story, because they’re identical to what you’d pay on LillyDirect — no telehealth markup. Here’s what the two drugmakers now charge on the same platform:

• Zepbound (Lilly, GLP-1 injection): from $299/month
• Foundayo (Lilly, oral pill, launched April 2026): from $149/month
• Wegovy pill (Novo Nordisk): from $149/month
• Wegovy injector pen (Novo Nordisk): from $199/month

Two things jump out. First, the oral pills from both companies land at the same $149 — a tidy little price match that tells you how hard they’re competing for the pill-not-needle crowd. Second, Lilly’s injectable is the priciest item on the menu at $299, a reminder that the shot still commands a premium even as pills crowd in underneath it.

There’s a strings-attached clause too: Hims & Hers agreed not to sell compounded versions or knockoffs of Lilly’s obesity drugs (MoneyCheck). That matters more than it sounds, and we’ll get to why.

Zoom out and the momentum is all Lilly’s. The company raised its full-year revenue forecast by $5 billion just last week, and it now carries a market value around $1.2 trillion (MoneyCheck). Foundayo, its oral pill, arrived in April, a few months behind Novo’s Wegovy pill — and Lilly is clearly in a hurry to make up ground on the oral side.

⚠️ The Catch

Here’s the awkward part. Hims & Hers built a large chunk of its weight-loss business selling compounded GLP-1s — cheaper, pharmacy-mixed copies that were legal to sell while the branded drugs were in shortage. Now it’s signing a deal that explicitly bars it from selling knockoffs of Lilly’s drugs. The company is trading its scrappy, discount-copy past for a seat at the branded table.

And the stock, despite Friday’s pop, is having a rough year. HIMS is down about 26% in 2026 and has fallen 37% since its July 6 close of $38.28, closing below its 200-day moving average for four straight sessions (MoneyCheck). A 7% premarket bounce is nice; it doesn’t undo that.

Then there’s the obvious one: $299 a month is still $299 a month. Self-pay convenience isn’t the same as affordability. These deals make the drugs easier to buy, not cheap.

🎯 What Happens Next

Watch what employers do in 2027. Analysts think Hims & Hers could actually benefit if companies drop weight-loss drug coverage next year, because every patient who loses their insurance route becomes a self-pay customer — exactly the kind Hims is now set up to serve (Reuters via Investing.com).

Expect the pill price war to intensify. With Lilly’s Foundayo and Novo’s Wegovy pill both sitting at $149 on the same site, the next move is almost certainly one of them blinking on price, bundling, or dosing to break the tie.

And keep an eye on LillyDirect. If the Hims channel converts better, Lilly may lean harder into third-party platforms rather than its own storefront — a quiet admission that meeting customers where they already are beats making them come to you.

🧩 Bigger Picture

For two years the GLP-1 story was about supply: shortages, waitlists, compounding pharmacies filling the gaps. That era is closing. Both Lilly and Novo can now make enough, so the fight has shifted to distribution and price — who gets the drug into your hands with the fewest clicks and the smallest sticker.

Telehealth platforms like Hims are morphing into something like pharmacies-as-marketplaces, where the drugmakers rent shelf space and compete head to head in front of the same shopper. That’s a very different, and much lower-margin, world than the one where you simply couldn’t get the drug at any price.

The weight-loss boom just graduated from a supply problem to a checkout problem — and the checkout page, it turns out, is worth fighting over.

---

Sources

• Reuters via Investing.com — Lilly to sell obesity drugs directly on Hims & Hers site
• MoneyCheck — Hims & Hers stock rises 7% as Lilly drugs move onto its platform
• Securities.io — Lilly and Hims & Hers formalize self-pay obesity drug access

❓ Quick answers

How much does Zepbound cost on Hims & Hers?

Zepbound starts at $299/month self-pay and Lilly's Foundayo pill starts at $149/month, matching LillyDirect prices, as of the Nov 6, 2026 deal (Reuters).

Why did Hims & Hers stock go up?

HIMS rose about 7% on Nov 6, 2026 because Lilly's obesity drugs can now be bought directly on its platform instead of being routed off-site to LillyDirect (MoneyCheck).

Does Hims & Hers now sell both Lilly and Novo weight-loss drugs?

Yes. Novo Nordisk's Wegovy and Ozempic have been on the platform since March 2026, and Lilly's Zepbound and Foundayo joined directly on Nov 6, 2026 (Reuters).